Research

Hormonal

Semaglutide administration (up to 1 mg weekly) produces significant weight and BMI reduction in obese patients with kidney failure undergoing dialysis, with a side effect profile comparable to non-dialysis populations.

If you are on dialysis and obese, semaglutide injections (starting at 0.25mg and increasing to 1mg weekly) can help you lose significant weight (average 4.6kg in 12 weeks) with manageable side effects like mild nausea. This weight loss may allow you to qualify for kidney transplantation, which offers better survival and quality of life than remaining on dialysis. Consult your nephrologist about this off-label use.

ModerateSupportsMEDIUM confidence
Semaglutide treatment resulted in significant reduction in weight and BMI in patients with obesity undergoing dialysis, while maintaining an acceptable side effect profile comparable to that of the non-dialysis population.
Lenka Vanek et al. · Diabetes Obesity and Metabolism · 2024

Why this rating

Prospective observational study with a small sample size (n=13) and lack of randomization, though results were statistically significant.

Source

Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open‐label study

Lenka Vanek et al. · Diabetes Obesity and Metabolism · 2024

DOI 10.1111/dom.15967

cohort · n=13Cited 22×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →